ReviewWorld journal of cardiology2026
Metabolic dysfunction-associated steatotic liver disease and heart failure with preserved ejection fraction: A state-of-the-art review.
Review in World journal of cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Beyond Weight Loss: Tirzepatide as a Metabolic Disease-Modifying Strategy for Metabolic Dysfunction-Associated Steatohepatitis: A Narrative Review.Health science reports · 2026Article
- Comparative performance of insulin resistance-related indices in predicting adverse cardiovascular events among individuals with NAFLD and MASLD: a multi-center cohort study.Cardiovascular diabetology · 2026Observational
- Liver fibrosis in metabolic dysfunction-associated steatotic liver disease: epidemiology, risk stratification and therapeutics.BMJ open gastroenterology · 2026Review
- Risk of Long-Term Clozapine Medication over Decades for Cardiac Adverse Events Including Heart Failure and Its Pathophysiology: A Japan and China Retrospective Cohort Analysis.Medical sciences (Basel, Switzerland) · 2026Article
- Glucagon-Like Peptide-1 Receptor Agonist Therapy Reduces Fibrosis-4 Index in Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastroenterology research · 2026Article
- Metabolic Dysfunction-Associated Steatotic Liver Disease as a Systemic Driver of Heart Failure With Preserved Ejection Fraction: Mechanistic Insights and Emerging Therapeutic Perspectives.Reviews in cardiovascular medicine · 2026Review
- A Supervised, Online, Home-Based Eccentric Resistance Exercise Program for Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease.Gastroenterology research · 2026Article
- Editorial: The MASLD spectrum: an emerging epidemic of cardiometabolic and extra-hepatic dimensions.Frontiers in epidemiology · 2026Article
- Tirzepatide in Metabolically Dysfunctional-Associated Steatohepatitis (MASH): A Bibliometric and Evidence-Based Review.Journal of diabetes research · 2026Review
- Predicting Clinically Significant Portal Hypertension in MASLD Using Routine Ultrasound and Clinical Data: A Retrospective Cohort Study.BioMed research international · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic dysfunction-associated steatotic liver disease (MASLD) has rapidly become the leading cause of chronic liver disease and cirrhosis worldwide, driven by the global surge in metabolic disorders such as obesity, diabetes, hypertension, and dyslipidemia. In parallel, heart failure with preserved ejection fraction (HFpEF) has surpassed heart failure with reduced ejection fraction (HFrEF) as the predominant form of heart failure, particularly in individuals with metabolic comorbidities. Mounting evidence points to a significant overlap in the pathophysiological underpinnings of MASLD and HFpEF, with metabolic dysfunction serving as a common foundation. This review synthesizes current knowledge on the mechanistic links between MASLD and HFpEF, examining metabolic, inflammatory, and fibrotic pathways. We also explore the clinical implications of this association, including diagnostic considerations and therapeutic targets. Shared risk factors and inflammatory pathways have highlighted a strong bidirectional association between MASLD and cardiovascular diseases, particularly HFpEF. Significantly, the degree of hepatic fibrosis in MASLD correlates with HFpEF prognosis and severity, emphasizing the systemic nature of these conditions. Emerging pharmacological and lifestyle-based interventions aimed at managing both conditions underscore the importance of integrated, multidisciplinary care in improving long-term outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.